Spotlight Growth
No Result
View All Result
Wednesday, March 22, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

ChemoCentryx, Inc. (NASDAQ: CCXI) Receives FDA Approval of TAVNEOS for Treatment of ANCA-Associated Vasculitis

by admin
October 8, 2021
in Bio/Med/Pharma
0
ChemoCentryx NASDAQ CCXI FDA Approval TAVNEOS Spotlight Growth

ChemoCentryx NASDAQ CCXI FDA Approval TAVNEOS Spotlight Growth

ChemoCentryx, Inc. (NASDAQ: CCXI) is engaged as a biopharmaceutical company, which is focused on the research and development of new treatments for inflammation and autoimmune diseases and cancer. The company develops its treatments to target the chemokine and chemoattractant systems.

Shares of the biopharma company are soaring 69% through early trading on Friday, October 8, 2021. Over the past three months, ChemoCentryx has seen average daily volume of 1.85 million shares. However, volume of 58.02 million shares or dollar volume of $1.88 billion, has already exchanged hands through early trading Friday.

ChemoCentryx’s shares are surging after the company announced that its treatment, TAVNEOS, has received approval from the U.S. Food and Drug Administration (FDA). TAVNEOS is an orally-administered selective complement 5a receptor inhibitor, which seeks to treat adult patients suffering from ANCA-associated vasculitis. TAVNEOS now is the first FDA approved oral inhibitor of the complement C5a receptor.

ANCA-associated vasculitis is a systemic autoimmune disease that involves an over-activation of the complement system leading to neutrophils. This can cause inflammation and destroy small blood vessels, which can cause fatal organ failure.

“Today is a momentous day in the history of ChemoCentryx; the culmination of decades of effort aimed at offering new hope to patients with this and other debilitating and deadly diseases,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “We look forward to making TAVNEOS available to clinicians and patients in the next few weeks. We thank the Agency for their collaboration and consideration and we are also immensely grateful to the pioneering scientists, clinicians and patients who believed in the promise of TAVNEOS and who have worked tirelessly to make it a reality, along with my dedicated and talented colleagues at ChemoCentryx.”

Disclosure: Neither Spotlight Growth nor its officers have any position or relationship with any companies mentioned in this article. No payment was made to create this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.

Tags: biopharma stocksbiopharmaceuticalsbiotechbiotech stocksCCXICCXI stockChemoCentryxcommon stockemerging growthinvestinginvestmentmedicalmedical stocksmicrocap stocksNASDAQNASDAQ stocksnewspharmaceuticalspublic companyRobinhoodrobinhood stockssalesservicessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstock market newsstocksstocks to watchtradingtreatmentwallstreetbetswebullWSB
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
89bio NASDAQ ETNB Phase 2b ENLIVEN Trial Pegozafermin NASH Spotlight Growth

89bio (NASDAQ: ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved Primary Endpoints For Treatment of Nonalcoholic Steatohepatitis (NASH)

March 22, 2023
U.S. Xpress NYSE USX Knight-Swift Transportation NYSE KNX Acquisition Spotlight Growth

U.S. Xpress Enterprises (NYSE: USX) Enters Into Acquisition Agreement With Knight-Swift Transportation (NYSE: KNX) Valued at $808 Million

March 21, 2023
Axon Enterprise Logo

Axon Enterprise (NASDAQ: AXON) Maintains its Market Dominance with Strong Growth

March 20, 2023
PureCycle Technologies NASDAQ PCT PureFive Distribution Agreement Formerra Spotlight Growth

PureCycle Technologies (NASDAQ: PCT) Enters Into Strategic Distribution Partnership With Formerra For its PureFive UPR Polypropylene Resin Product

March 16, 2023

Recent News

89bio NASDAQ ETNB Phase 2b ENLIVEN Trial Pegozafermin NASH Spotlight Growth

89bio (NASDAQ: ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved Primary Endpoints For Treatment of Nonalcoholic Steatohepatitis (NASH)

March 22, 2023
U.S. Xpress NYSE USX Knight-Swift Transportation NYSE KNX Acquisition Spotlight Growth

U.S. Xpress Enterprises (NYSE: USX) Enters Into Acquisition Agreement With Knight-Swift Transportation (NYSE: KNX) Valued at $808 Million

March 21, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested